E. Renzoni (London, United Kingdom), J. Morisset (Montréal (QC), Canada)
Late Breaking Abstract - Clinical utility of basophil activating test (BAT) in subjects with drug-induced lung disease.
S. Suzuki (Tokyo, Japan), T. Homma (Tokyo, Japan), S. Ohta (Tokyo, Japan), K. Fujiwara (Tokyo, Japan), Y. Miyata (Tokyo, Japan), Y. Kishino (Tokyo, Japan), A. Tanaka (Tokyo, Japan), T. Ohnishi (Tokyo, Japan), H. Sagara (Tokyo, Japan)
|    |
A prognostic staging system for rheumatoid arthritis-associated interstitial lung disease
H. Kim (Seoul, Republic of Korea), M. Han (Seoul, Republic of Korea), J. Joseph (Rochester, MN, United States of America), G. Cross (London, United Kingdom), J. Barnett (London, United Kingdom), D. Kim (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea)
| |
Prognostic impact of bronchoalveolar lavage lymphocytosis in patients with chronic Hypersensitivity Pneumonitis
J. Wälscher (Heidelberg, Germany), B. Gross (Heidelberg, Germany), J. Bruhwyler (Gembloux, Belgium), J. Morisset (Quebec, Canada), C. Heussel (Heidelberg, Germany), F. Lasitschka (Heidelberg, Germany), F. Herth (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany)
| |
Lung involvement and clinical characteristics in anti-MDA5 positive connective tissue diseases
F. Meloni (Pavia, Italy), J. Cifrian (Santander, Spain), A. Pesci (Monza, Italy), R. Coelho (Lisboa, Portugal), M. Mejia (Mexico City, Mexico), F. Bonella (Essen, Germany), J. Perrin (Metz, France), P. Ceruti (Brescia, Italy), R. García-Sevila (Alicante, Spain), E. Bargagli (Firenze, Italy), S. Hirschi (Strasbourg, France), V. Codullo (Pavia, Italy), L. Cavagna (Pavia, Italy)
| |
Genetic variant in MMP2 increases the risk to develop autoantibodies in patients with Hypersensitivity Pneumonitis
I. Buendia Roldán (Ciudad de Mexico, Mexico), L. Santiago Ruiz (Ciudad de Mexico, Mexico), G. Perez Rubio (Ciudad de Mexico, Mexico), M. Mejia (Ciudad de Mexico, Mexico), M. Montaño (Ciudad de Mexico, Mexico), R. Falfan Valencia (Ciudad de Mexico, Mexico)
| |
Cystic lesion in myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)- positive interstitial pneumonia: radiological and pathological anaylsis
E. Tabata (Yokohama, Japan), T. Takemura (Tokyo, Japan), T. Baba (Yokohama, Japan), E. Hagiwara (Yokohama, Japan), H. Nakagawa (Yokohama, Japan), T. Katano (Yokohama, Japan), G. Matama (Yokohama, Japan), N. Aiko (Yokohama, Japan), K. Isomoto (Yokohama, Japan), R. Ohtoshi (Yokohama, Japan), R. Shintani (Yokohama, Japan), S. Sadoyama (Yokohama, Japan), S. Ikeda (Yokohama, Japan), H. Yamakawa (Yokohama, Japan), T. Niwa (Yokohama, Japan), T. Oda (Yokohama, Japan), R. Okuda (Yokohama, Japan), A. Sekine (Yokohama, Japan), H. Kitamura (Yokohama, Japan), S. Komatsu (Yokohama, Japan), T. Iwasawa (Yokohama, Japan), T. Ogura (Yokohama, Japan)
|  |
The effect of Rituximab treatment on progression of Rheumatoid arthritis-associated interstitial lung disease
S. Sra (London, United Kingdom), K. Myall (London, United Kingdom), B. Lams (London, United Kingdom), S. Agarwal (London, United Kingdom), A. West (London, United Kingdom)
| |
Safety of benzodiazepines and opioids in interstitial lung disease: national prospective study
S. Bajwah (London, United Kingdom), J. Davies (London, United Kingdom), H. Tanash (Lund, Sweden), D. Currow (Sydney, Australia), M. Ekstrom (Lund, Sweden)
| |